The Janus kinase inhibitor baricitinib, in combination with narrowband ultraviolet B therapy, improved vitiligo, according to ...

Oral JAK inhibitors offer patients with AD a ... Source Reference: Haag C, et al "A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes ...

JAK inhibitors have since emerged as a promising ... et al "Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort ...

Combining ultraviolet (UV) phototherapy with the Janus kinase (JAK) inhibitor baricitinib (Olumiant) helped patients with ...

For years now, investigators have been studying the Janus kinase (JAK) inhibitor in combination with other drugs, both in first-line treatment and refractory disease. Abstracts and oral ...

Additionally, the Janus kinase (JAK) family has emerged as another important target for therapeutic intervention. JAK inhibitors, such as ruxolitinib and upadacitinib, have been approved for ...